LeukoCore™ Solid Tumor Cancer Leukopak for Immunology Research

LeukoCore™ Solid Tumor Cancer Leukopak biospecimens are collected from donors clinically diagnosed with Solid Tumor Cancer through IRB-approved apheresis procedures. Each leukopak contains large quantities of peripheral blood mononuclear cells (PBMCs), making it ideal for immune profiling, cytokine analysis, and drug development research related to Solid Tumor Cancer-associated inflammation and immune dysregulation.

Product Features

• Research Use Only (RUO) human leukopaks
• Clinically confirmed Solid Tumor Cancer donors
• High cell yield for large-scale studies
• Processed and shipped within 24 hours of collection
• Fresh or cryopreserved options available
• IRB-approved and ethically sourced
• Infectious disease testing
• HLA-A typing
• Screen donors with LeukoLot™

Donor Metadata

• Verified Solid Tumor Cancer diagnosis from healthcare providers
• Donor demographics: age, sex assigned at birth, race/ethnicity
• Self-reported medication history and allergies
• Relevant clinical data Solid Tumor Cancer

Applications

• Immune cell characterization in Solid Tumor Cancer
• Therapeutic development and screening
• Cell-based assays and cytokine profiling
• Multi-omics studies single-cell sequencing

Compliance and Quality Assurance

• Collected under IRB oversight with donor e-consent (21 CFR Part 11 compliant)
• HIPAA-compliant handling of donor information
• Rigorous donor screening and documentation

Ordering & Customization

Solid Tumor Cancer Leukopak samples are available fresh or cryopreserved. For international shipping or regulatory documentation, please contact to confirm regional compliance and shipping availability.